Karyopharm Therapeutics Inc Net Asset Quality Index
Karyopharm Therapeutics Inc net asset quality index. Karyopharm Therapeutics Inc (KPTI) has a Net Asset Quality Index of -296.6% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $111.32 Million minus total liabilities of $441.49 Million yields net assets of $-330.17 Million. A higher index indicates a stronger, lower-leverage balance sheet. See KPTI net assets for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Karyopharm Therapeutics Inc (2011–2025)
Net asset quality index of Karyopharm Therapeutics Inc from 2011 to 2025. This chart shows how Karyopharm Therapeutics Inc's Net Asset Quality Index has evolved across 15 annual periods from 2011 to 2025. As of June 2026, the index stands at -296.6%, representing net assets of $-330.17 Million against total assets of $111.32 Million USD. Check strategic asset allocation of Karyopharm Therapeutics Inc to assess the company's strategic physical and investment asset allocation.
Karyopharm Therapeutics Inc Net Asset Quality Index by Year (2011–2025)
Karyopharm Therapeutics Inc net asset quality index by year from 2011 to 2025. The table below presents the year-by-year Net Asset Quality Index for Karyopharm Therapeutics Inc from 2011 to 2025, covering 15 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Karyopharm Therapeutics Inc market cap and net worth.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | -270.2% | $-292.93 Million | $108.42 Million | $401.34 Million | ▼ -157.1 pp |
| 2024 | -113.1% | $-186.02 Million | $164.42 Million | $350.44 Million | ▼ -56.5 pp |
| 2023 | -56.6% | $-136.21 Million | $240.44 Million | $376.64 Million | ▼ -52.0 pp |
| 2022 | -4.7% | $-16.66 Million | $358.17 Million | $374.83 Million | ▲ +21.4 pp |
| 2021 | -26.1% | $-79.67 Million | $305.31 Million | $384.98 Million | ▼ -42.2 pp |
| 2020 | 16.1% | $50.55 Million | $313.05 Million | $262.50 Million | ▼ -0.7 pp |
| 2019 | 16.9% | $49.77 Million | $294.96 Million | $245.19 Million | ▼ -36.8 pp |
| 2018 | 53.7% | $183.17 Million | $341.19 Million | $158.02 Million | ▼ -18.1 pp |
| 2017 | 71.8% | $129.46 Million | $180.29 Million | $50.83 Million | ▼ -18.1 pp |
| 2016 | 89.9% | $162.24 Million | $180.38 Million | $18.14 Million | ▼ -2.1 pp |
| 2015 | 92.1% | $198.37 Million | $215.44 Million | $17.08 Million | ▼ -1.8 pp |
| 2014 | 93.9% | $206.79 Million | $220.34 Million | $13.54 Million | ▼ -4.1 pp |
| 2013 | 97.9% | $154.93 Million | $158.23 Million | $3.29 Million | ▲ +2224.3 pp |
| 2012 | -2126.4% | $-27.88 Million | $1.31 Million | $29.19 Million | ▼ -1951.3 pp |
| 2011 | -175.1% | $-12.65 Million | $7.22 Million | $19.88 Million | — |